{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/antiplatelet-treatment/prescribing-information/prasugrel/","result":{"pageContext":{"chapter":{"id":"52159350-4f8e-536b-99c4-a75908d6233a","slug":"prasugrel","fullItemName":"Prasugrel","depth":2,"htmlHeader":"<!-- begin field a857adb5-bee1-41f2-b61a-a781008ea458 --><h2>Prasugrel</h2><!-- end field a857adb5-bee1-41f2-b61a-a781008ea458 -->","summary":"","htmlStringContent":"<!-- begin item 1971b17f-bbdd-48e6-b68a-a781008ea2f8 --><!-- end item 1971b17f-bbdd-48e6-b68a-a781008ea2f8 -->","topic":{"id":"86dfa76b-bc1a-5d4b-bf7c-018d5d031947","topicId":"a68e1521-d84e-4abb-bb17-6186ba7a891a","topicName":"Antiplatelet treatment","slug":"antiplatelet-treatment","lastRevised":"Last revised in August 2020","chapters":[{"id":"af85e41e-4007-5daa-bc95-35aa03621ea0","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"db8ef934-0123-530e-9f34-52d23ea99e56","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"ebaf9360-bb92-51bc-8aba-ac3293fa1416","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"b34f13e6-85f8-5c85-b2f7-5678c0779a07","slug":"changes","fullItemName":"Changes"},{"id":"9532ea0d-f7f7-5a08-9076-dedbf78ca97d","slug":"update","fullItemName":"Update"}]},{"id":"0370616e-85d0-5654-b5ad-ea9980ad8eaa","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"24bebba9-1157-505c-834d-bf255dd856a9","slug":"goals","fullItemName":"Goals"},{"id":"b1ab86f3-b045-5a24-b8ea-506ae6fa94c8","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"cb61b0c8-a7f6-5e31-af33-9c4ade31a493","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"19dcf0a2-d60c-5fe4-94b7-d902d7cc17f8","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"758947ec-f9bc-59c9-a07f-663f738f5428","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"8c16356c-f5cf-54fc-99e8-ccc08af83ec7","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"30e0cacd-1816-520e-8f4a-aba760ce71f5","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"9e23a119-ae6d-5e11-9691-ed23c4016c39","slug":"definition","fullItemName":"Definition"},{"id":"2ef5b7fd-3211-5769-8a72-083d9f8c40c8","slug":"mechanism-of-action","fullItemName":"Mechanism of action"},{"id":"ef9f4561-2787-59c9-974b-b656929c553c","slug":"indications","fullItemName":"Indications"},{"id":"7692771a-8763-57f6-b4fe-d4711f820cfb","slug":"complications","fullItemName":"Complications"}]},{"id":"d31d1a85-d8c2-5598-b7e0-e8b2da36e45c","fullItemName":"Management","slug":"management","subChapters":[{"id":"81844a0f-b280-563a-b66c-4a5dba6e1e9c","slug":"primary-prevention-of-cvd","fullItemName":"Scenario: Primary prevention of CVD"},{"id":"c2fb4ffa-788d-5d77-a694-3e30c3008d35","slug":"secondary-prevention-of-cvd","fullItemName":"Scenario: Secondary prevention of CVD"}]},{"id":"85828cd6-6943-58a7-9657-71760be76497","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"d408bf47-147e-5914-ab35-c4142ec2a33e","slug":"low-dose-aspirin","fullItemName":"Low dose aspirin"},{"id":"4098d4bf-7db2-5e79-bdec-17a2bbfaca6a","slug":"clopidogrel","fullItemName":"Clopidogrel"},{"id":"d5d8e5ca-9f57-5ac9-955b-614b85700f3e","slug":"dipyridamole","fullItemName":"Dipyridamole"},{"id":"52159350-4f8e-536b-99c4-a75908d6233a","slug":"prasugrel","fullItemName":"Prasugrel"},{"id":"92100407-8f08-53c0-8df1-1e802f4dcbe9","slug":"ticagrelor","fullItemName":"Ticagrelor"}]},{"id":"ec007ae2-2b14-50b1-a091-3875c81c5adb","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"f54cfffb-be9e-5523-a47f-c1100845c9c4","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"4ce7f1c7-df35-54c7-9f8b-b1aefe5762f1","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"f4d603b9-b19a-53ac-8058-8c414be0a10b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"69fb4d5c-2946-5ef6-8c7f-b5f81dd52f9c","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d1e16069-862f-500a-9f58-e84cb201da64","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"fab694fa-9176-5402-b7b5-729a22dd611f","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"3852e22b-c968-5afe-81be-ac1efce390da","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"85828cd6-6943-58a7-9657-71760be76497","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"6f5595bb-0d13-52f3-bc52-52e23a12264b","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 0ca4ee3c-05ec-4a1d-8a55-a78100910737 --><h3>Contraindications and cautions </h3><!-- end field 0ca4ee3c-05ec-4a1d-8a55-a78100910737 -->","summary":"","htmlStringContent":"<!-- begin item 6b25e8ac-11cc-426c-9f05-a78100910609 --><!-- begin field 3b0a1212-4ffc-4a2f-b2f4-a78100910737 --><ul><li><strong>Do not prescribe prasugrel to people with:</strong><ul><li>Active pathological bleeding.</li><li>A history of stroke or transient ischaemic attack.</li><li>Severe hepatic impairment.</li></ul></li><li><strong>Prescribe prasugrel with caution to people:</strong><ul><li>At increased risk of bleeding (for example, from recent trauma, surgery, gastrointestinal bleeding, or active peptic ulcer disease).</li><li>Taking drugs that increase risk of bleeding (for example, aspirin).</li><li>Who are elderly (aged over 75 years) or weigh less than 60 kg — a maintenance dose of 5 mg daily should be used.</li><li>With renal or hepatic impairment.</li><li>Undergoing elective surgery — discontinue 7 days before if antiplatelet effect is not desirable.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">BNF 75, 2018</a>] </p><!-- end field 3b0a1212-4ffc-4a2f-b2f4-a78100910737 --><!-- end item 6b25e8ac-11cc-426c-9f05-a78100910609 -->","subChapters":[]},{"id":"682f6f1a-6d22-5be1-b13c-b136731bf99f","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 00d2d7d4-34ae-444d-859f-a78100912232 --><h3>Adverse effects</h3><!-- end field 00d2d7d4-34ae-444d-859f-a78100912232 -->","summary":"","htmlStringContent":"<!-- begin item 1e48d742-e184-4eb3-be77-a78100912171 --><!-- begin field 8836386a-9932-4a42-ae76-a78100912232 --><ul><li><strong>Gastrointestinal (GI) </strong>— GI haemorrhage (common); retroperitoneal haemorrhage, rectal haemorrhage, gingival bleeding (uncommon).</li><li><strong>Blood and lymphatic system</strong> — anaemia (common).<ul><li><strong>Rarely:</strong> thrombocytopenia.</li><li><strong>Frequency unknown:</strong> thrombotic thrombocytopenia purpura (TTP).</li></ul></li><li>Other adverse effects include:<ul><li>Epistaxis, haemoptysis.</li><li>Eye haemorrhage.</li><li>Haematuria.</li><li>Haematoma.</li><li>Hypersensitivity, angioedema.</li><li>Intracranial haemorrhage.</li><li>Rash, ecchymosis.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">BNF 75, 2018</a>]</p><!-- end field 8836386a-9932-4a42-ae76-a78100912232 --><!-- end item 1e48d742-e184-4eb3-be77-a78100912171 -->","subChapters":[]},{"id":"6ca87f82-b308-502a-b703-83d5555a5980","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 9a766aec-2722-4d6c-8552-a781009143fb --><h3>Drug interactions </h3><!-- end field 9a766aec-2722-4d6c-8552-a781009143fb -->","summary":"","htmlStringContent":"<!-- begin item 829030b1-5f23-44ba-9dfc-a781009142f9 --><!-- begin field 0f42d578-dd1d-41f1-a764-a781009143fb --><ul><li><strong>Increased risk of bleeding if prasugrel is combined with other drugs that also increase the risk of bleeding.</strong> Examples include: <ul><li>Other antiplatelets drugs — aspirin, clopidogrel, or ticagrelor.</li><li>Nonsteroidal anti-inflammatory drugs (NSAIDs) — ibuprofen, diclofenac.</li><li>Oral and parenteral anticoagulants — warfarin, heparin, dabigatran.</li><li>Selective serotonin reuptake inhibitors (SSRIs) — fluoxetine, sertraline.</li><li>Serotonin and noradrenaline reuptake inhibitors (SNRIs) — venlafaxine, duloxetine.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">BNF 75, 2018</a>]</p><!-- end field 0f42d578-dd1d-41f1-a764-a781009143fb --><!-- end item 829030b1-5f23-44ba-9dfc-a781009142f9 -->","subChapters":[]},{"id":"ae45aa3b-731f-5c6f-829f-1c17bf020955","slug":"pregnancy-breastfeeding","fullItemName":"Pregnancy and breastfeeding","depth":3,"htmlHeader":"<!-- begin field 7ea7cf19-3e6a-4fe2-aa62-a8e80109d576 --><h3>Pregnancy and breastfeeding</h3><!-- end field 7ea7cf19-3e6a-4fe2-aa62-a8e80109d576 -->","summary":"","htmlStringContent":"<!-- begin item 10d62aa1-0b5d-45fa-b7f5-a8e80109d478 --><!-- begin field 1761509e-8caa-45f2-a091-a8e80109d576 --><h4>Pregnancy</h4><ul><li>The manufacturer advises that prasugrel should only be used in women who are pregnant if the potential benefits outweigh the risks.</li></ul><h4>Breastfeeding</h4><ul><li>It is unknown whether prasugrel is excreted in breastmilk.</li><li>Use in women who are breastfeeding is not recommended.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">BNF 75, 2018</a>]</p><!-- end field 1761509e-8caa-45f2-a091-a8e80109d576 --><!-- end item 10d62aa1-0b5d-45fa-b7f5-a8e80109d478 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}